Da4b95bc-74e3-4590-910d-45a6cc0df665 - samples

ABSTRACT: ABACUS is a single arm phase 2 study that investigated 2 cycles of atezolizumab (1200mg Q3) prior to cystectomy in 95 patients with muscle invasive transitional cell cancer (T2-4N0M0). Pathological complete response (pCR) occurring in ≥20% of patients was the primary endpoint. Biomarker analysis on sequential tissue was a co-primary endpoint. This dataset includes the processed data from FMOne.

PROVIDER: EGAD00001006201 | EGA |

REPOSITORIES: EGA